SPRINGWORKS THERAPEUTICS INC. - COMMON STOCK

40,28

07-февраля-25 16:45:00

15 мин. задержка

Акции

+1,00

+2,55%

Сегодняшний диапазон

39,10 - 40,95

ISIN

N/A

Источник

NASDAQ

SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025

30 янв 2025 07:00:50 Источник Nasdaq GlobeNewswire
SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference

13 янв 2025 06:30:33 Источник Nasdaq GlobeNewswire
SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

03 янв 2025 06:30:46 Источник Nasdaq GlobeNewswire
SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

26 ноя 2024 07:00:26 Источник Nasdaq GlobeNewswire
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference

12 ноя 2024 09:25:59 Источник Nasdaq GlobeNewswire
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

12 ноя 2024 06:30:21 Источник Nasdaq GlobeNewswire
SpringWorks Therapeutics Announces Mirdametinib Data to be Presented at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting

11 ноя 2024 07:00:56 Источник Nasdaq GlobeNewswire
SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical Oncology

11 ноя 2024 06:30:11 Источник Nasdaq GlobeNewswire
SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors to be Presented at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting

07 ноя 2024 06:30:00 Источник Nasdaq GlobeNewswire
SpringWorks Therapeutics to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference

05 ноя 2024 07:00:32 Источник Nasdaq GlobeNewswire
SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

22 окт 2024 07:00:14 Источник Nasdaq GlobeNewswire
FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN

28 авг 2024 06:30:35 Источник Nasdaq GlobeNewswire
SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

07 авг 2024 06:30:35 Источник Nasdaq GlobeNewswire
SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors

29 июл 2024 06:30:11 Источник Nasdaq GlobeNewswire
SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024

23 июл 2024 07:00:02 Источник Nasdaq GlobeNewswire
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

01 июл 2024 06:30:00 Источник Nasdaq GlobeNewswire
SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

05 июн 2024 07:00:52 Источник Nasdaq GlobeNewswire
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

23 май 2024 17:13:28 Источник Nasdaq GlobeNewswire
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference

08 май 2024 07:00:27 Источник Nasdaq GlobeNewswire
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates

02 май 2024 06:30:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.